Platelet‑derived growth factor‑beta as a new marker of deep venous thrombosis

Background: deep venous thrombosis (dvt) is associated with significant morbidity and mortality. thus, there is a great need to demonstrate a more efficient biomarker that would confirm the diagnosis of dvt. our work aimed to evaluate the role of platelet‑derived growth factor‑beta (pdgf‑b) as a new marker of dvt and its correlation with other radiological and laboratory tools used for the diagnosis. materials and methods: a case–control study enrolled forty patients selected from our university hospital between april 2018 and august 2018, who divided into two groups: group i (n = 20) consisted of patients diagnosed with acute venous thrombosis and group ii (n = 20) consisted of patients diagnosed with chronic venous thrombosis. twenty samples were collected from age‑ and gender‑matched apparently healthy controls to be used as a control. venous duplex ultrasonography, routine laboratory investigations, d‑dimer (dd), and protein expression of pdgf‑b were performed on all patients. results: there was a highly significant increase in a protein expression of pdfg‑b in all cases of acute and chronic venous thrombosis compared to the control group with p < 0.001; furthermore, it was more specific than dd for the detection of dvt (specificity 95% and 90%, respectively). conclusion: our study submits a novel association of pdgf‑b plasma levels with dvt, and pdgf‑b is considered to be a more specific indicator for dvt than is dd.